Collapse all
The Business Model Canvas reveals a high-value, specialized B2B service that bridges the gap between academic botanical research and industrial drug discovery. The model's success depends on establishing rigorous standardization and intellectual property frameworks to attract major pharmaceutical players.
4 Academic Institutions Partnerships with entities like Cape Peninsula University of Technology to access existing botanical databases and research methodologies. CSIR Collaboration with the Council for Scientific and Industrial Research for shared laboratory infrastructure and regulatory guidance. Indigenous Community Leaders Partnerships to ensure ethical sourcing of plant species and fair benefit-sharing agreements (Nagoya Protocol compliance). Specialized Logistics Providers Cold-chain transport services to maintain the integrity of volatile bio-active compounds during transit. 4 Bio-Active Screening Executing high-throughput assays to identify pharmacological activity in indigenous plant extracts. Compound Validation Performing secondary validation to ensure 'hits' are reproducible and not false positives. Botanical Library Curation Building and maintaining a standardized library of indigenous plant extracts for rapid testing. IP Documentation Creating detailed dossiers on bio-active leads to facilitate patent filing for pharmaceutical clients. 4 Analytical Instrumentation High-performance liquid chromatography (HPLC) and mass spectrometry equipment for compound identification. Botanical Database Proprietary data on indigenous plant species and their known traditional medicinal uses. Phytochemistry Expertise Specialized scientists capable of isolating complex organic molecules from raw plant matter. Regulatory Certifications GLP (Good Laboratory Practice) certifications required for data to be accepted by pharmaceutical R&D. 3 Risk Reduction Providing a validated 'hit-list' of extracts, significantly lowering the failure rate of early-stage drug discovery. Accelerated Discovery Reducing the time pharmaceutical companies spend on raw botanical screening through a pre-validated library. Ethical Sourcing Assurance Handling the complex legal and ethical requirements of accessing indigenous genetic resources for global firms. 3 Strategic Partnerships Long-term R&D collaborations with firms like Novartis and AstraZeneca for specific therapeutic targets. Consultative Service Working closely with client researchers to tailor screening parameters to their specific drug pipeline needs. Contractual SLAs Strict Service Level Agreements regarding data accuracy, confidentiality, and delivery timelines. 3 Direct B2B Sales Direct outreach to R&D procurement heads at major pharmaceutical companies. Scientific Conferences Presenting validated findings at pharmacology and botany symposiums to attract industry interest. Institutional Referrals Leveraging relationships with the WHO and CSIR to be recommended as a trusted screening partner. 3 Global Pharma Giants Companies like Novartis and AstraZeneca seeking novel lead compounds for new drug pipelines. Regional Pharmaceutical Firms Companies like Aspen Pharmacare focusing on regional health needs and indigenous medicine. Public Health Organizations Entities like the WHO interested in validating traditional medicines for global health accessibility. 3 Laboratory Overheads High costs associated with maintaining specialized equipment and chemical reagents. Specialized Labor Competitive salaries for PhD-level phytochemists and molecular biologists. Compliance and Legal Costs for ensuring adherence to the Nagoya Protocol and international biodiversity laws. 3 Screening Service Fees Fixed-price contracts for screening a specific number of plant species against a target. Success-Based Milestones Payments triggered when a bio-active 'hit' is validated and passed to the client. Licensing Royalties Percentage-based royalties on drugs developed from leads identified by the service. The idea has clearly identified high-value B2B customers and a specific value proposition, making it ideal for mapping the revenue and delivery model. · Generated 2026-09-07 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated